Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - metoclopramide hydrochloride monohydrate, quantity: 10.537 mg (equivalent: metoclopramide hydrochloride, qty 10 mg) - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; lactose monohydrate; pregelatinised maize starch; magnesium stearate; maize starch - indications as at 10 august 1994: adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. intramuscular administration of maxolon facilitates the absorption of a range of drugs including the absorption of aspirin in people with migraine. maxolon has been found useful in the management of gastric retention after gastric surgery. maxolon may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, maxolon should be discontinued. young adults and children: the use of maxolon in patients under 20 years should be restricted to the following s

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - digoxin, quantity: 0.0625 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; magnesium stearate; povidone; indigo carmine; oxidised maize starch; rice starch - indications as at 26 july 2000 : congestive heart failure - lanoxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. lanoxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because lanoxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - lanoxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - digoxin, quantity: 0.25 mg/ml - injection, solution - excipient ingredients: citric acid monohydrate; dibasic sodium phosphate; propylene glycol; water for injections; ethanol - indications as at 26 july 2000 : congestive heart failure - lanoxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. lanoxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because lanoxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - lanoxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - digoxin, quantity: 25 microgram/ml - injection, solution - excipient ingredients: ethanol; propylene glycol; citric acid; dibasic sodium phosphate; water for injections - indications as at 26 july 2000 : congestive heart failure - lanoxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. lanoxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because lanoxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - lanoxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lorazepam, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; lactose monohydrate; polacrilin potassium - indications as at 22 february 1995: ativan is indicated for: 1. management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. anxiety or tension associated with the stress of everyday life usually does not require treatment with anxiolytic. the physician should periodically reassess the usefulness of the drug for the individual patient. 2. pre-surgical medication taken the night before surgery and/or 1-2 hours prior to the surgical procedure.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lorazepam, quantity: 1 mg - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; lactose monohydrate; polacrilin potassium - indications as at 22 february 1995: ativan is indicated for: 1. management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. anxiety or tension associated with the stress of everyday life usually does not require treatment with anxiolytic. the physician should periodically reassess the usefulness of the drug for the individual patient. 2. pre-surgical medication taken the night before surgery and/or 1-2 hours prior to the surgical procedure.

Israel - Tiếng Anh - Ministry of Health

cts chemical industries ltd, israel - valproic acid as sodium - tablets enteric coated - valproic acid as sodium 500 mg - valproic acid - valproic acid - generalized or partial epilepsy, secondary generalized epilepsy, mixed forms of epilepsy.

Israel - Tiếng Anh - Ministry of Health

cts chemical industries ltd, israel - valproic acid as sodium - syrup - valproic acid as sodium 40 mg/ml ml - valproic acid - valproic acid - generalized or partial epilepsy secondary generalized epilepsy and mixed forms of epilepsy.

Israel - Tiếng Anh - Ministry of Health

cts chemical industries ltd, israel - valproic acid as sodium - tablets enteric coated - valproic acid as sodium 200 mg - valproic acid - valproic acid - anti-epileptic.

Israel - Tiếng Anh - Ministry of Health

cts chemical industries ltd, israel - valproic acid as sodium - solution (oral) - valproic acid as sodium 200 mg/ml - valproic acid - treatment of generalized or partial epilepsy secondary generalized epilepsy and mixed forms of epilepsy.